Cellid seeks patent protection for vaccine antigen technology in China and India, expanding its Asian business foothold

[Financial News] Cellid is expanding the scope of its efforts to secure overseas rights to key technology used in developing COVID-19 vaccines.
Cellid announced on the 7th that patents for its antigen platform had been approved for registration in China and India. The patents cover technology that improves structural stability when the spike protein of the COVID-19 virus is used as a vaccine antigen. Related patents have already been registered in South Korea, the United States, Japan, Russia and Vietnam, and the latest decisions mark progress toward securing rights in China and India as well.
The spike protein contains a “furin cleavage site,” where enzymes can act to cut the protein. If an antigen produced in the body after vaccination is separated at this site, the time it remains in the body may be reduced. Cellid said, “Our proprietary technology addresses this structural limitation and improves the antigen’s stability and ability to induce an immune response.”
The company is developing a COVID-19 vaccine by combining its antigen technology with its independently developed adenovirus vector technology. It has completed patent registration for its vector platform in South Korea, the United States, Europe and other regions. Cellid believes that securing rights to both platforms will help differentiate its technology in overseas business and technology-transfer negotiations.
The company is preparing follow-up clinical trials to address variant strains. According to Cellid, the safety of “AdCLD-CoV19-1 OMI” has been confirmed, and it plans an additional clinical trial to assess the immunogenicity of “AdCLD-CoV19-1 XFG,” which incorporates variants recommended for 2026–2027.
Production of the clinical trial drug for this purpose has been completed. The company is making preparations with the aim of applying for approval of its clinical trial plan at the end of this year or early next year. Ultimately, it plans to commercialize a COVID-19 vaccine that can be manufactured and supplied domestically.
CEO Kang Chang-yul said, “The decisions to grant patents in China and India are an achievement that strengthens the overseas business foundations of our antigen and vector platforms. Building on the intellectual property rights we secure in the two countries, we will pursue global technology-transfer opportunities and strengthen domestic vaccine supply capacity by commercializing homegrown vaccines.”

[email protected] Choi Doo-sun Reporter